Risk factors
TAO Synergies (TAOX) risk factors
Item 1A of every TAO Synergies Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors68 risks30 new5 dropped7 reworded
Company pivoted into a crypto strategy aiming to acquire $100 million of TAO tokens, relying heavily on consultant James Altucher.
Filed Mar 31, 2026 - FY2024 10-K risk factors43 risks
TAO Synergies faces high reliance on its lead drug Bryostatin-1, which failed its primary Phase 2 endpoint.
Filed Mar 27, 2025